

Clinical Policy: Peginterferon beta-1a (Plegridy)

Reference Number: CP.PHAR.271

Effective Date: 08/16

Last Review Date: 08/17

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

The intent of the criteria is to ensure that patients follow selection elements established by Centene[®] clinical policy for peginterferon beta-1a (Plegridy[®]).

Policy/Criteria

It is the policy of health plans affiliated with Centene Corporation[®] that Plegridy is **medically necessary** for the following indications:

I. Initial Approval Criteria

A. Multiple Sclerosis (must meet all):

1. Diagnosis of clinically isolated syndrome or relapsing-remitting multiple sclerosis (MS);
2. Prescribed by or in consultation with a neurologist;
3. Age \geq 18 years;
4. Member will not use other disease modifying therapies for MS concurrently;
5. Dose does not exceed 125 mcg every 14 days (1 pen or syringe every 14 days).

Approval duration: 6 months

B. Other diagnoses/indications: Refer to CP.PHAR.57 - Global Biopharm Policy

II. Continued Approval

A. Multiple Sclerosis (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Member is responding positively to therapy (e.g., improved or maintained disease control evidenced by decreased or stabilized Expanded Disability Status Scale score or reduction in relapses or magnetic resonance imaging lesions);
3. Member is not using other disease modifying therapies for MS concurrently;
4. If request is for a dose increase, new dose does not exceed 125 mcg every 14 days (1 pen or syringe every 14 days).

Approval duration: 12 months

B. Other diagnoses/indications (1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy; or
2. Refer to CP.PHAR.57 - Global Biopharm Policy.

CLINICAL POLICY
Peginterferon beta-1a

Background

Description/Mechanism of Action:

Plegridy is a pegylated interferon beta-1a. The interferon beta-1a portion is produced as a glycosylated protein using genetically-engineered Chinese hamster ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of the recombinant interferon beta-1a is identical to that of the human interferon beta counterpart. The mechanism by which Plegridy exerts its effects in patients with multiple sclerosis is unknown.

Formulations:

Plegridy is supplied as a sterile, clear liquid for subcutaneous injection in two presentations, a prefilled pen and a prefilled syringe

- Each prefilled pen is a single-dose, disposable, injection device that contains a glass syringe with 0.5 mL of solution of Plegridy with 63 mcg, 94 mcg, or 125 mcg of peginterferon beta-1a.
- Each prefilled syringe contains a single-dose of 0.5 mL of solution of Plegridy with 63 mcg, 94 mcg, or 125 mcg of peginterferon beta-1a.

FDA Approved Indication(s):

Plegridy is an interferon beta/subcutaneous injection indicated for:

- Treatment of patients with relapsing forms of multiple sclerosis.

Appendices

Appendix A: Abbreviation Key

FDA: Food and Drug Administration

MS: multiple sclerosis

Reviews, Revisions, and Approvals	Date	Approval Date
Policy split from CP.PHAR.18 MS Treatments. Criteria: added max dosing, clarified monotherapy restriction, removed re-authorization requirement for documented adherence, modified efficacy criteria from “No increase in neurologic dysfunction/disability as a result of relapses or progressive disease, including a change in diagnostic status from RRMS to SPMS” to “Responding positively to therapy”.	06/16	08/16
Added age requirement. Removed contraindication and reasons to discontinue. Removed MRI requirement.	07/17	08/17

References

1. Plegridy Prescribing Information. Cambridge, MA: Biogen Inc.; July 2016. Available at <http://www.plegridy.com>. Accessed June 16, 2017.
2. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. *Neurology*. 2002; 58(2): 169-178.

3. Olek MJ. Diagnosis of multiple sclerosis in adults. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2016. Available at www.UpToDate.com. Accessed June 13, 2017.
4. Costello K, Halper J, Kalb R, Skutnik L, Rapp R. The use of disease-modifying therapies in multiple sclerosis, principles and current evidence – a consensus paper by the Multiple Sclerosis Coalition. July 2016. Accessed June 13, 2017.

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound

CLINICAL POLICY

Peginterferon beta-1a

by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs and LCDs and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.